| Market Capitalization (Millions $) |
405 |
| Shares
Outstanding (Millions) |
104 |
| Employees |
42 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-78 |
| Cash Flow (TTM) (Millions $) |
-83 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Rezolute Inc is a clinical-stage biopharmaceutical company that is focused on the development of drugs for the treatment of rare and metabolic diseases. The company's mission is to develop and commercialize therapies that can improve the lives of patients who suffer from rare diseases.
Founded in 2010, Rezolute Inc is headquartered in Redwood City, California. The company has a highly experienced management team that consists of industry veterans with a track record of success in drug development and commercialization.
Rezolute Inc is primarily focused on the development of two drug candidates, RZ358 and RZ40 RZ358 is a potential treatment for congenital hyperinsulinism (CHI), a rare genetic disorder that affects infants and children. RZ402 is a potential treatment for diabetic foot ulcers (DFU), a complication of diabetes that can lead to amputation.
The company's lead drug candidate, RZ358, is currently in a Phase 2b clinical trial for the treatment of CHI. Rezolute Inc has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for RZ358.
RZ402 is currently in pre-clinical development for the treatment of DFU. The company has received Orphan Drug Designation from the FDA for RZ40
Rezolute Inc has a partnership with Teva Pharmaceuticals, a leading global pharmaceutical company, for the development and commercialization of RZ358. The partnership includes an up-front payment to Rezolute Inc, as well as development and commercialization milestones.
In addition to its drug development programs, Rezolute Inc has a research collaboration with the Stanford University School of Medicine on the development of an implantable insulin pump for the treatment of diabetes.
Overall, Rezolute Inc is a promising biopharmaceutical company that is focused on developing innovative therapies for patients who suffer from rare and metabolic diseases. With its experienced management team, strong pipeline of drug candidates, and strategic partnerships, the company is well positioned for future success in the industry.
Company Address: 275 Shoreline Drive, Suite 500 Redwood City 94065 CA
Company Phone Number: 206-4507 Stock Exchange / Ticker: NASDAQ RZLT
|
0.46%